238 related articles for article (PubMed ID: 9254887)
1. A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes.
Dong Z; Crawford HC; Lavrovsky V; Taub D; Watts R; Matrisian LM; Colburn NH
Mol Carcinog; 1997 Jul; 19(3):204-12. PubMed ID: 9254887
[TBL] [Abstract][Full Text] [Related]
2. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response.
Li JJ; Westergaard C; Ghosh P; Colburn NH
Cancer Res; 1997 Aug; 57(16):3569-76. PubMed ID: 9270030
[TBL] [Abstract][Full Text] [Related]
4. Induced expression of dominant-negative c-jun downregulates NFkappaB and AP-1 target genes and suppresses tumor phenotype in human keratinocytes.
Li JJ; Cao Y; Young MR; Colburn NH
Mol Carcinog; 2000 Nov; 29(3):159-69. PubMed ID: 11108661
[TBL] [Abstract][Full Text] [Related]
5. Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation.
Dhar A; Hu J; Reeves R; Resar LM; Colburn NH
Oncogene; 2004 May; 23(25):4466-76. PubMed ID: 15064752
[TBL] [Abstract][Full Text] [Related]
6. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion.
Young MR; Li JJ; Rincón M; Flavell RA; Sathyanarayana BK; Hunziker R; Colburn N
Proc Natl Acad Sci U S A; 1999 Aug; 96(17):9827-32. PubMed ID: 10449779
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element.
Li JJ; Dong Z; Dawson MI; Colburn NH
Cancer Res; 1996 Feb; 56(3):483-9. PubMed ID: 8564958
[TBL] [Abstract][Full Text] [Related]
8. Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis.
Matthews CP; Birkholz AM; Baker AR; Perella CM; Beck GR; Young MR; Colburn NH
Cancer Res; 2007 Mar; 67(6):2430-8. PubMed ID: 17363560
[TBL] [Abstract][Full Text] [Related]
9. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells.
Dong Z; Birrer MJ; Watts RG; Matrisian LM; Colburn NH
Proc Natl Acad Sci U S A; 1994 Jan; 91(2):609-13. PubMed ID: 8290571
[TBL] [Abstract][Full Text] [Related]
10. Tumor promoter-induced ornithine decarboxylase gene expression occurs independently of AP-1 activation.
Jansen AP; Colburn NH; Verma AK
Oncogene; 1999 Oct; 18(42):5806-13. PubMed ID: 10523861
[TBL] [Abstract][Full Text] [Related]
11. Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-kappaB activation.
Hsu TC; Nair R; Tulsian P; Camalier CE; Hegamyer GA; Young MR; Colburn NH
Cancer Res; 2001 May; 61(10):4160-8. PubMed ID: 11358840
[TBL] [Abstract][Full Text] [Related]
12. SAG/ROC2/Rbx2 is a novel activator protein-1 target that promotes c-Jun degradation and inhibits 12-O-tetradecanoylphorbol-13-acetate-induced neoplastic transformation.
Gu Q; Tan M; Sun Y
Cancer Res; 2007 Apr; 67(8):3616-25. PubMed ID: 17440073
[TBL] [Abstract][Full Text] [Related]
13. c-jun and multistage carcinogenesis: association of overexpression of introduced c-jun with progression toward a neoplastic endpoint in mouse JB6 cells sensitive to tumor promoter-induced transformation.
Watts RG; Ben-Ari ET; Bernstein LR; Birrer MJ; Winterstein D; Wendel E; Colburn NH
Mol Carcinog; 1995 May; 13(1):27-36. PubMed ID: 7766308
[TBL] [Abstract][Full Text] [Related]
14. bcl-2 enhancement of malignant transformation in mouse epidermal JB6 cells.
Amstad PA; Liu H; Ichimiya M; Chang S; Berezesky IK; Trump BF
Mol Carcinog; 1997 Oct; 20(2):231-9. PubMed ID: 9364213
[TBL] [Abstract][Full Text] [Related]
15. Differential c-jun expression in response to tumor promoters in JB6 cells sensitive or resistant to neoplastic transformation.
Ben-Ari ET; Bernstein LR; Colburn NH
Mol Carcinog; 1992; 5(1):62-74. PubMed ID: 1543542
[TBL] [Abstract][Full Text] [Related]
16. Two novel glycosides from the fruits of Morinda citrifolia (noni) inhibit AP-1 transactivation and cell transformation in the mouse epidermal JB6 cell line.
Liu G; Bode A; Ma WY; Sang S; Ho CT; Dong Z
Cancer Res; 2001 Aug; 61(15):5749-56. PubMed ID: 11479211
[TBL] [Abstract][Full Text] [Related]
17. Differential inhibition of UVB-induced AP-1 and NF-kappaB transactivation by components of the jun bZIP domain.
Cooper S; Ranger-Moore J; Bowden TG
Mol Carcinog; 2005 Jun; 43(2):108-16. PubMed ID: 15791649
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the antioxidative property of morusin in blocking phorbol ester-induced malignant transformation of JB6 P
Cheng PS; Hu CC; Wang CJ; Lee YJ; Chung WC; Tseng TH
Chem Biol Interact; 2017 Feb; 264():34-42. PubMed ID: 28108223
[TBL] [Abstract][Full Text] [Related]
19. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines.
Mackay AR; Ballin M; Pelina MD; Farina AR; Nason AM; Hartzler JL; Thorgeirsson UP
Invasion Metastasis; 1992; 12(3-4):168-84. PubMed ID: 1284126
[TBL] [Abstract][Full Text] [Related]
20. Increased erythroid potentiating activity/tissue inhibitor of metalloproteinases and jun/fos transcription factor complex characterize tumor promoter-induced megakaryoblastic differentiation of K562 leukemia cells.
Alitalo R; Partanen J; Pertovaara L; Hölttä E; Sistonen L; Andersson L; Alitalo K
Blood; 1990 May; 75(10):1974-82. PubMed ID: 2159816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
